Municipal mortality due to thyroid cancer in Spain

BMC Public Health

Volumn 6, Issue , 2006, Pages

  Lope, Virginia ^a   Pollán, Marina ^a   Pérez Gómez, Beatriz ^a   Aragonés, Nuria ^a   Ramis, Rebeca ^a   Gómez Barroso, Diana ^a   López Abente, Gonzalo ^a  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; ENDEMIC DISEASE; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ASSOCIATION; HUMAN; MALE; RISK ASSESSMENT; RISK FACTOR; SPAIN; THYROID CANCER; AUDIOVISUAL EQUIPMENT; BAYES THEOREM; CITY; CLASSIFICATION; GEOGRAPHY; GOITER; HEALTH; MORTALITY; RISK; STATISTICS AND NUMERICAL DATA; THYROID NEOPLASMS; TRENDS;

BAYES THEOREM; CITIES; FEMALE; GEOGRAPHY; GOITER; HUMANS; MALE; MAPS AS TOPIC; MORTALITY; RISK; RISK ASSESSMENT; SPAIN; THYROID NEOPLASMS; URBAN HEALTH;

EID: 33846640774     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-6-302     Document Type: Article

References (59)

1. Moreno V, Gonzalez J, Soler M, Bosch F, Kogevinas M, Borras J: [Cancer incidence estimation in Spain: period 1993-1996]. Gac Sanit 2001, 15:380-388.
2. López-Abente G, Pollán M, Aragonés N, Pérez-Gómez B, Lope V, Suárez B, Hernández V, Cárdaba M: La Situación del cáncer en España [The cancer situation in Spain]. Madrid, Ministerio de Sanidad y Consumo; 2005.
3. Mortalidad por cáncer y otras causas [Mortality by cancer and other causes] 2005 [http://cne.isciii.es].
4. Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon, IARCPress; 2004.
5. Berrino F, Capocaccia R, Coleman MP, Esteve J, Gatta G, Hakulinen T, Micheli A, Sant M, Verdecchia A: Survival of cancer patients in Europe. The Eurocare-3 Study. Ann Oncol 2003, 14 Suppl 5:v128-v149.
6. Fraker D, Skarulis M, Livolsi V: Thyroid Tumors. In DeVita V, Hellman S, Rosenberg S. Cancer Principles & Practice of Oncology. 6th edition Philadelphia, Lippincott Williams & Wilkins; 2001:1740-1763.
7. Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, McTiernan A, Kolonel L, Mark SD, Mabuchi K, Jin F, Wingren G, Galanti R, Hallquist A, Glattre E, Lund E, Levi F, Linos D, Ron E: A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 1999, 10:583-595.
8. Ron E: Thyroid Cancer. In Schottenfeld, Fraumeni. Cancer Epidemiology and Prevention. Second edition Second edition edition. New York, Oxford University Press; 1996:1000-1021.
9. La Vecchia C, Ron E, Franceschi S, Dal Maso L, Mark SD, Chatenoud L, Braga C, Preston-Martin S, McTiernan A, Kolonel L, Mabuchi K, Jin F, Wingren G, Galanti MR, Hallquist A, Lund E, Levi F, Linos D, Negri E: A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 1999, 10:157-166.
10. Memon A, Darif M, Al Saleh K, Suresh A: Epidemiology of reproductive and hormonal factors in thyroid cancer: evidence from a case-control study in the Middle East. Int J Cancer 2002, 97:82-89.
11. Negri E, Dal Maso L, Ron E, La Vecchia C, Mark SD, Preston-Martin S, McTiernan A, Kolonel L, Yoshimoto Y, Jin F, Wingren G, Rosaria GM, Hardell L, Glattre E, Lund E, Levi F, Linos D, Braga C, Franceschi S: A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control 1999, 10:143-155.
12. Zivaljevic V, Vlajinac H, Jankovic R, Marinkovic J, Dzodic R, Sipeti GS, Paunovic I, Diklic A, Zivaljevic B: Case-control study of female thyroid cancer - menstrual, reproductive and hormonal factors. Eur J Cancer Prev 2003, 12:63-66.
13. Bosetti C, Negri E, Kolonel L, Ron E, Franceschi S, Preston-Martin S, McTiernan A, Dal Maso L, Mark SD, Mabuchi K, Land C, Jin F, Wingren G, Galanti MR, Hallquist A, Glattre E, Lund E, Levi F, Linos D, La Vecchia C: A pooled analysis of case-control studies of thyroid cancer. VII. Cruciferous and other vegetables (International). Cancer Causes Control 2002, 13:765-775.
14. Galanti MR, Hansson L, Bergstrom R, Wolk A, Hjartaker A, Lund E, Grimelius L, Ekbom A: Diet and the risk of papillary and follicular thyroid carcinoma: a population-based case-control study in Sweden and Norway. Cancer Causes Control 1997, 8:205-214.
15. Markaki I, Linos D, Linos A: The influence of dietary patterns on the development of thyroid cancer. Eur J Cancer 2003, 39:1912-1919.
16. Memon A, Varghese A, Suresh A: Benign thyroid disease and dietary factors in thyroid cancer: a case-control study in Kuwait. Br J Cancer 2002, 86:1745-1750.
17. Alsanea O, Clark OH: Familial thyroid cancer. Curr Opin Oncol 2001, 13:44-51.
18. Lope V, Pollán M, Pérez-Gómez B, Aragonés N, Suárez B, Carrasco JM, Rodríguez S, Ramis R, Boldo E, López-Abente G: Incidencia y mortalidad por cáncer de tiroides en España [Incidence and mortality by thyroid cancer in Spain]. Boletín Epidemiológico Semanal 2004, 12:161-172.
19. Elliot P, Wakefield C, Best NG, Briggs D: Spatial Epidemiology: Methods and Applications Oxford, Oxford University Press; 2000.
20. Lawson A, Biggeri A, Böhning D, Lesaffre E: Disease mapping and risk assessment for public health Chichester, Wiley; 1999.
21. Richardson S, Thomson A, Best N, Elliott P: Interpreting posterior relative risk estimates in disease-mapping studies. Environ Health Perspect 2004, 112:1016-1025.
22. Besag J, York J, Mollié A: Bayesian image restoration, with applications in spatial statistics. Annals of the Institute of Statistics and Mathematics 1991:1-59.
23. Clayton DG, Bernardinelli L, Montomoli C: Spatial correlation in ecological analysis. Int J Epidemiol 1993, 22:1193-1202.
24. Lawson A, Browne W, Vidal Rodeiro C: Diseases Mapping with WinBUGS and MLwiN. West Susset, England, Wiley; 2003.
25. Gilks WR, Richardson S, Spiegelhalter DJ: Markov Chain Monte Carlo in Practice London, Chapman Hall; 1996.
26. Spiegelhalter D, Thomas D, Best N, Lunn D: WinBUGS User Manual, version 1.4 Cambridge, MRC Biostatistics Unit; 2003.
27. Smith BJ: Bayesian Output Analysis Program (BOA). 0.99.1 for S-PLUS and R [Online ]. 2001 [http://www.publichealth.uiowa.edu/BOA].
28. Vila L: La deficiencia de yodo en España: un problema pendiente que urge resolver. Endocrinol Nutr 2002, 49:1-4.
29. Díaz-Cadórniga FJ, Delgado-Álvarez E: Grupo de trastornos por deficiencia de Yodo. Déficit de yodo en España: situación actual. Endocrinol Nutr 2004:2-13.
30. Madueno Caro AJ, Cabezas Saura PB, Diaz OJ, Benitez RE, Ruiz GM, Gomez A: [Prevalence of goitre and iodine deficiency in a school population from a traditionally endemic health area]. Aten Primaria 2001, 27:258-262.
31. Rodríguez-Ojea A: Deficiencia de yodo y sus implicaciones para la salud del hombre. Revista Cubana Aliment Nutr 1996, 10:.
32. Fleites G: Dieta y cáncer del tiroides. Rev Cubana Oncol 1999, 15:119-130.
33. de Diego GG, Jara AA: [Relation between endemic goiter and cancer of the thyroid]. Rev Clin Esp 1987, 181:378-382.
34. Fioretti F, Tavani A, Gallus S, Franceschi S, Negri E, La Vecchia C: Case-control study of thyroid cancer in Northern Italy: attributable risk. Int J Epidemiol 1999, 28:626-630.
35. Galanti MR, Sparen P, Karlsson A, Grimelius L, Ekbom A: Is residence in areas of endemic goiter a risk factor for thyroid cancer? Int J Cancer 1995, 61:615-621.
36. Levi F, Franceschi S, La Vecchia C, Negri E, Gulie C, Duruz G, Scazziga B: Previous thyroid disease and risk of thyroid cancer in Switzerland. Eur J Cancer 1991, 27:85-88.
37. Franceschi S: Iodine intake and thyroid carcinoma - a potential risk factor. Exp Clin Endocrinol Diabetes 1998, 106 Suppl 3:S38-S44.
38. Bakiri F, Djemli FK, Mokrane LA, Djidel FK: The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma. Cancer 1998, 82:1146-1153.
39. Garrido M, Damiano A, Lorenzo V: [Endemic goiter in Galicia]. Rev Clin Esp 1966, 103:196-199.
40. Pombo M, Barreiro J, Tojo R: Tiroiditis y bocio no tóxico. Patología tiroidea. 3.er Curso de Formación de Postgrado. Sevilla, 1997 1998 [http://www.seep.es/privado/download.asp?url= Publicaciones/patolog.pdf]. Barcelona, T.G. Soler, S.A.
41. Tojo R, Fraga JM, Escobar del Rey F, Rodríguez A, Vázquez E, Esquete C: Estudio del bocio endémico en Galicia. Repercusión sobre el crecimiento y desarrollo. Endocrinología 1987, 34:48-52.
42. Consumo de frutas y hortalizas. Galicia 2004 [http://www.infoagro. com/frutas/consumo/galicia.asp].
43. Samir M, el Awady MY: Serum selenium levels in multinodular goitre. Clin Otolaryngol Allied Sci 1998, 23:512-514.
44. Thilly CH, Vanderpas JB, Bebe N, Ntambue K, Contempre B, Swennen B, Moreno-Reyes R, Bourdoux P, Delange F: Iodine deficiency, other trace elements, and goitrogenic factors in the etiopathogeny of iodine deficiency disorders (IDD). Biol Trace Elem Res 1992, 32:229-243.
45. Toxicological Profile for Selenium. Public Health Statement for Selenium 2003 [http://www.atsdr.cdc.gov/toxprofiles/phs92.html]. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service
46. Cocho JA: Selenio: conocimiento actual y situación en España. 2000 [http://www.seqc.net/article/articleview/66/1/23/].
47. Isidro San Juan ML, Vidal CA, Argueso AA, Alvarez CP, Vidal Pardo JI, Cordido CF: [Iodine deficiency disorder persistance after introduction of iodized salt in a previously endemic goiter area]. An Med Interna 2004, 21:171-174.
48. Díaz J, Vázquez E, Fernández G, Colón C, Bacariza F: Impacto del uso de la sal yodada en los escolares de la provincia de Lugo: su repercusión sobre el grado de bocio y la yoduria. Endocrinología 1993, 40:284-288.
49. Delgado Álvarez E, Díaz-Cadórniga FJ, Valdés Cañedo MM, Méndez García A, Bobis Rodríguez ML, Tartón García T, Menéndez Prada T: Nutrición de yodo en los escolares asturianos tras 18 años de yodoprofilaxis con sal: ¿erradicación del bocio endémico? Endocrinol Nutr 2001, 48:14.
50. Martínez E, Suárez C, San Miguel P: Epidemiología del cáncer de tiroides en Asturias. Cirugía Española 1986, XL:667-673.
51. Cañada A, Rodríguez V: Atlas de incidencia de cáncer en Asturias. 1982-1993: Mapas municipales y evolución temporal. Consejería de Salud y Servicios Sanitarios. Dirección General de Salud Pública. Principado de Asturias; 2000.
52. Suárez JB, Bello L, Betancor P: Aproximación epidemiológica del estudio del bocio en las Canarias orientales (Gran Canaria - Fuerteventura - Lanzarote). Rev San Hig Púb 1986, 60:651-677.
53. WHO Global Database on Iodine Deficiency. Spain. 2004 [http://www3.who.int/whosis/mn/mn_iodinmn_iodine_database.cfm?path=whosis,mn, mn_iodine,mn_iodine_data,mn_iodine_data_database&lan guage=english].
54. Ron E, Saftlas AF: Head and neck radiation carcinogenesis: epidemiologic evidence. Otolaryngol Head Neck Surg 1996, 115:403-408.
55. Schneider AB, Pinsky S, Bekerman C, Ryo UY: Characteristics of 108 thyroid cancers detected by screening in a population with a history of head and neck irradiation. Cancer 1980, 46:1218-1227.
56. Tucker MA, Jones PH, Boice JD Jr., Robison LL, Stone BJ, Stovall M, Jenkin RD, Lubin JH, Baum ES, Siegel SE, .: Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 1991, 51:2885-2888.
57. López-Abente G, Pollán M, Escolar A, Errezola M, Abraira V: Atlas de Mortalidad por Cáncer y Otras Causas en España 1978-1992 Madrid, Ministerio de Sanidad y Consumo; 2001.
58. Quindos Poncela LS, Fernandez PL, Gomez AJ, Sainz C, Fernandez JA, Suarez ME, Martin Matarranz JL, Cascon MC: Natural gamma radiation map (MARNA) and indoor radon levels in Spain. Environ Int 2004, 29:1091-1096.
59. Frich L, Glattre E, Akslen LA: Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiol Biomarkers Prev 2001, 10:113-117.